HIND earnings analysis
What we found in HIND's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q excerpt does not include the condensed financial statements or MD&A, so current-quarter revenue, margins, EPS, balance-sheet changes, cash flow, segment performance, and quantitative guidance cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter. Risk factors were unchanged from the 2025 Form 10-K filed March 18, 2026, supporting a neutral assessment rather than a directional earnings call.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure Controls Effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
- No Material Control Changes
- The company reported that there were no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Existing Risk Profile Unchanged
- The company stated that there were no material changes to the risk factors in Item 1A of its 2025 Form 10-K filed March 18, 2026; therefore, the filing does not provide evidence that prior risks have been reduced.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text. The filing only states that no material changes were made to the risk factors in the 2025 Form 10-K.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Vyome Holdings, Inc. reported Q1 2026 results with significant declines in both revenue and net loss compared to the prior period. Revenue decreased to $31,591 from $198,581 in Q1 2025, yielding a net loss of $985,521…
- 10-K · March 18, 2026
- Vyome Holdings (formerly ReShape Lifesciences) completed its merger with Vyome on August 15, 2025 and is a clinical-stage specialty pharmaceutical company focused on repurposing FDA‑approved molecules for rare…
- 10-Q · November 14, 2024
- ReShape Lifesciences improved top-line and margin performance in Q3 2024 with revenue of $2,292 (vs $2,155 in Q3 2023) and gross margin rising to ~62.8% from ~59.8%; operating loss narrowed to $(1,761) from $(3,880).…
- 10-K · April 1, 2024
- ReShape Lifesciences reported 2023 revenue of $8.678M with a net loss of $11.387M, an improvement versus 2022’s $11.240M revenue and $46.214M net loss. The company received FDA approval for the Lap-Band 2.0 in December…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HIND makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever